Information  X 
Enter a valid email address

Galen Hldgs (WCRX)

  Print      Mail a friend

Wednesday 29 May, 2002

Galen Hldgs

EGM Statement

Galen Holdings PLC
29 May 2002


For Immediate Release                                        29 May 2002


                               Galen Holdings PLC
                      Statement regarding disposal of CTS



GALEN HOLDINGS PLC ('GALEN' or the 'Company')

Result of Extraordinary General Meeting

29 May 2002


The Board of Galen is pleased to announce that at today's Extraordinary General
Meeting of the Company, the Ordinary Resolution in respect of the proposed
disposal of the Clinical Trial Services Business, as detailed in the circular
sent to shareholders on 8 May 2002, was approved by shareholders. Accordingly,
completion is expected to occur on 31 May 2002 subject to approval from
competition authorities.


Commenting on the result of the vote, John King, Executive Chairman of Galen
commented;

'We are pleased to complete this important step in our transition to a pharma
focused company. Our key promoted products show continued success in the
marketplace and are exhibiting strong growth. This growth, supported by a strong
pipeline with two NDA's filed and one more due for filing early next year,
augers well for continued success. Our best wishes for the future go to all our
colleagues in CTS.'





                                      ###





For further information please contact:


GALEN
David G. Kelly,                                  Telephone: +44 (0) 28 3833 4974
Senior Vice President, Finance and Planning

CREDIT SUISSE FIRST BOSTON
Andrew Christie                                  Telephone: +44 (0) 207 888 8888

FINANCIAL DYNAMICS
Fiona Noblet / Sophie Pender-Cudlip              Telephone: +44 (0) 20 7831 3113











                      This information is provided by RNS
            The company news service from the London Stock Exchange